Search Results

Validation and molecular integration of the RR6 model to predict survival after 6 months of therapy with ruxolitinib.

• Authors : Coltro G; Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy; CRIMM, Center for Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliero-Universitaria Careggi, Florence.

Subjects: Nitriles*/Nitriles*/Nitriles*/therapeutic use ; Pyrimidines*/Pyrimidines*/Pyrimidines*/therapeutic use ; Pyrazoles*/Pyrazoles*/Pyrazoles*/therapeutic use

• Source: Haematologica [Haematologica] 2024 Oct 01; Vol. 109 (10), pp. 3398-3403. Date of Electronic Publication: 2024 Oct 01.Publisher: Ferrata Storti Foundation Country of Publication: Italy NLM ID: 0417435 Publication Model: Electronic Cited

Record details

Prognostic stratification in venetoclax-based acute myeloid leukemia treatments: the molecular prognostic risk signature tested in a real-world setting.

• Authors : Ciolli G; Hematology Department, Azienda Ospedaliero-Universitaria Careggi, 50134 Florence.; Piccini M

• Source: Haematologica [Haematologica] 2024 Sep 05. Date of Electronic Publication: 2024 Sep 05.Publisher: Ferrata Storti Foundation Country of Publication: Italy NLM ID: 0417435 Publication Model: Print-Electronic Cited

Record details

Dexamethasone treatment for COVID-19 is related to increased mortality in hematologic malignancy patients: results from the EPICOVIDEHA registry.

• Authors : Aiello TF; Infectious Diseases Department, Hospital Clinic of Barcelona-IDIBAPS, Universitat de Barcelona, Barcelona.; Salmanton-Garcia J

Subjects: Dexamethasone*/Dexamethasone*/Dexamethasone*/therapeutic use ; Hematologic Neoplasms*/Hematologic Neoplasms*/Hematologic Neoplasms*/mortality ; Hematologic Neoplasms*/Hematologic Neoplasms*/Hematologic Neoplasms*/drug therapy

• Source: Haematologica [Haematologica] 2024 Aug 01; Vol. 109 (8), pp. 2693-2700. Date of Electronic Publication: 2024 Aug 01.Publisher: Ferrata Storti Foundation Country of Publication: Italy NLM ID: 0417435 Publication Model: Electronic Cited

Record details

BCL3 rearrangements in B-cell lymphoid neoplasms occur in two breakpoint clusters associated with different diseases.

• Authors : Carbo-Meix A; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona.; Guijarro F

Subjects: Leukemia, Lymphocytic, Chronic, B-Cell*/Leukemia, Lymphocytic, Chronic, B-Cell*/Leukemia, Lymphocytic, Chronic, B-Cell*/genetics ; Lymphoma, Large B-Cell, Diffuse*/Lymphoma, Large B-Cell, Diffuse*/Lymphoma, Large B-Cell, Diffuse*/genetics; Humans

• Source: Haematologica [Haematologica] 2024 Feb 01; Vol. 109 (2), pp. 493-508. Date of Electronic Publication: 2024 Feb 01.Publisher: Ferrata Storti Foundation Country of Publication: Italy NLM ID: 0417435 Publication Model: Electronic Cited

Record details

COVID-19 in adult acute myeloid leukemia patients: a long-term follow-up study from the European Hematology Association survey (EPICOVIDEHA).

• Authors : Marchesi F; Salmanton-García J ...

Subjects: COVID-19* ; Leukemia, Myeloid, Acute*/Leukemia, Myeloid, Acute*/Leukemia, Myeloid, Acute*/therapy ; Leukemia, Myeloid, Acute*/Leukemia, Myeloid, Acute*/Leukemia, Myeloid, Acute*/drug therapy

• Source: Haematologica [Haematologica] 2023 Jan 01; Vol. 108 (1), pp. 22-33. Date of Electronic Publication: 2023 Jan 01.Publisher: Ferrata Storti Foundation Country of Publication: Italy NLM ID: 0417435 Publication Model: Electronic Cited

Record details

Chromosome banding analysis and genomic microarrays are both useful but not equivalent methods for genomic complexity risk stratification in chronic lymphocytic leukemia patients.

• Authors : Ramos-Campoy S; Molecular Cytogenetics Laboratory, Pathology Department, Hospital del Mar, Barcelona, Spain; Translational Research on Hematological Neoplasms Group, Cancer Research Program, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Barcelona, Spain.

Subjects: Leukemia, Lymphocytic, Chronic, B-Cell*/Leukemia, Lymphocytic, Chronic, B-Cell*/Leukemia, Lymphocytic, Chronic, B-Cell*/diagnosis ; Leukemia, Lymphocytic, Chronic, B-Cell*/Leukemia, Lymphocytic, Chronic, B-Cell*/Leukemia, Lymphocytic, Chronic, B-Cell*/genetics; Chromosome Aberrations

• Source: Haematologica [Haematologica] 2022 Mar 01; Vol. 107 (3), pp. 593-603. Date of Electronic Publication: 2022 Mar 01.Publisher: Ferrata Storti Foundation Country of Publication: Italy NLM ID: 0417435 Publication Model: Electronic Cited

Record details

Heterogenous mutation spectrum and deregulated cellular pathways in aberrant plasma cells underline molecular pathology of light-chain amyloidosis.

• Authors : Chyra Z; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.; Sevcikova T

Subjects: Amyloidosis*/Amyloidosis*/Amyloidosis*/diagnosis ; Amyloidosis*/Amyloidosis*/Amyloidosis*/genetics ; Immunoglobulin Light-chain Amyloidosis*/Immunoglobulin Light-chain Amyloidosis*/Immunoglobulin Light-chain Amyloidosis*/diagnosis

• Source: Haematologica [Haematologica] 2021 Feb 01; Vol. 106 (2), pp. 601-604. Date of Electronic Publication: 2021 Feb 01.Publisher: Ferrata Storti Foundation Country of Publication: Italy NLM ID: 0417435 Publication Model: Electronic Cited

Record details

Combination therapy with interferon and ruxolitinib for polycythemia vera and myelofibrosis: are two drugs better than one?

• Authors : Silver RT; Richard T. Silver Myeloproliferative Neoplasms Center, Weill Cornell Medicine Division of Hematology-Oncology, New York, NY, USA. .

Subjects: Pharmaceutical Preparations* ; Polycythemia Vera*/Polycythemia Vera*/Polycythemia Vera*/drug therapy ; Primary Myelofibrosis*/Primary Myelofibrosis*/Primary Myelofibrosis*/drug therapy

• Source: Haematologica [Haematologica] 2020 Sep 01; Vol. 105 (9), pp. 2190-2191. Date of Electronic Publication: 2020 Sep 01.Publisher: Ferrata Storti Foundation Country of Publication: Italy NLM ID: 0417435 Publication Model: Electronic Cited

Record details

An agenda for future research projects in polycythemia vera and essential thrombocythemia.

• Authors : Barbui T; FROM Research Foundation, Papa Giovanni XXIII Hospital, Bergamo .; Vannucchi AM

Subjects: Polycythemia Vera*/Polycythemia Vera*/Polycythemia Vera*/diagnosis ; Thrombocythemia, Essential*/Thrombocythemia, Essential*/Thrombocythemia, Essential*/diagnosis ; Thrombocythemia, Essential*/Thrombocythemia, Essential*/Thrombocythemia, Essential*/genetics

• Source: Haematologica [Haematologica] 2020 Aug; Vol. 105 (8), pp. 1999-2003. Date of Electronic Publication: 2020 May 28.Publisher: Ferrata Storti Foundation Country of Publication: Italy NLM ID: 0417435 Publication Model: Print-Electronic Cited

Record details

Clinical outcomes under hydroxyurea treatment in polycythemia vera: a systematic review and meta-analysis.

• Authors : Ferrari A; FROM Research Foundation, ASST Papa Giovanni XXIII, Bergamo.; Carobbio A

Subjects: Hemorrhage/Hemorrhage/Hemorrhage/*mortality ; Hydroxyurea/Hydroxyurea/Hydroxyurea/*adverse effects ; Polycythemia Vera/Polycythemia Vera/Polycythemia Vera/*drug therapy

• Source: Haematologica [Haematologica] 2019 Dec; Vol. 104 (12), pp. 2391-2399. Date of Electronic Publication: 2019 May 23.Publisher: Ferrata Storti Foundation Country of Publication: Italy NLM ID: 0417435 Publication Model: Print-Electronic Cited

Record details